Piper Fatigue Scale (PFS)
Also known as: PFS
The Piper Fatigue Scale is a 22-item multidimensional self-report instrument that evaluates cancer-related fatigue across four conceptually distinct domains: behavioral/severity, affective/meaning, sensory, and cognitive/mood. Developed by Barbara Piper and colleagues in 1989 and revised in 1998, the PFS is grounded in a theoretical model of fatigue mechanisms and is widely used in oncology research and clinical practice to assess treatment-related and disease-related fatigue.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
PFS is appropriate for any cancer type and stage. Use in clinical trials as a secondary QoL endpoint, especially in trials testing supportive care interventions (exercise, nutrition, cognitive-behavioral therapy) for fatigue. Employ in observational studies examining fatigue prevalence and risk factors across treatment phases. In routine clinical practice, integrate into cancer center symptom-screening systems to identify patients with high fatigue burden and trigger supportive referrals (physiatry, psychology, survivorship). Particularly valuable for tracking fatigue trajectories during active treatment and post-treatment recovery.
Strengths & limitations
- Multidimensional theory-based design; directly addresses cancer-related fatigue mechanisms (behavioral, affective, sensory, cognitive). Subscale profiles enable hypothesis-driven, targeted interventions.
- Well-validated across cancer types and treatment phases; strong internal consistency (Cronbach α ≥0.80 for subscales) and test–retest reliability (ICC ≥0.75). Responsive to change with exercise, supportive care.
- Accessible 0–10 scale; easy patient comprehension and clinician interpretation. Minimal respondent burden (~5 min).
- Allows longitudinal tracking of fatigue patterns; sensitive to treatment-related fluctuations and trajectory changes.
- No fixed clinical cutoff for severity categories; 0–3, 4–6, 7–10 bands are empirical approximations, not validated thresholds. Clinical meaningfulness varies by population and context.
- Moderate ceiling effect in survivor populations with minimal residual fatigue; may not detect subtle improvements in already-low fatigue groups.
- Subscales are relatively short (5–6 items each); individual item fluctuations can shift subscale means noticeably. Small sample sizes may show high variability.
- Requires literacy; dependent on cognitive capacity to distinguish and rate four separate dimensions of fatigue.
Frequently asked
How are Piper subscale scores interpreted together?
Examine the profile pattern: high behavioral/severity indicates physical exhaustion or limitation; high affective/meaning indicates emotional distress or existential burden; high sensory indicates body-focused or localized symptoms; high cognitive/mood indicates mental fatigue or concentration problems. A 'mixed phenotype' (e.g., high across all four) suggests comprehensive, multifactorial fatigue requiring multimodal intervention. A 'selective profile' (e.g., high cognitive only) suggests targeted intervention (e.g., attention-training, cognitive rehabilitation).
What constitutes a clinically meaningful change in PFS scores?
Published estimates suggest a change of ≥1.0–1.5 points on the 0–10 scale for individual subscales or total score represents clinically meaningful improvement, particularly in intervention trials. Effect-size benchmarks (Cohen d) vary by population; small (~0.2), medium (~0.5), and large (~0.8) effects are standard. Use baseline fatigue severity and population-specific anchor data to contextualize changes.
Can the Piper Fatigue Scale be used in non-cancer chronic illness (e.g., ME/CFS, long COVID)?
The PFS was developed and extensively validated in cancer populations. Use in other chronic fatigue conditions requires dedicated validation studies. The four-dimensional model may be conceptually relevant, but normative data, cutoffs, and responsiveness are cancer-specific. Consult published validation studies before adapting PFS to non-cancer conditions; consider disease-specific fatigue instruments (Chalder Fatigue Scale, Fatigue Severity Scale) as alternatives.
How does Piper fatigue relate to depression or anxiety screening?
The Piper Affective/Meaning subscale may overlap with mood symptoms; however, it specifically measures fatigue-related emotional burden, not depression or anxiety per se. High affective/meaning does not diagnose depression but suggests emotional distress related to fatigue. Use concurrent screening tools (PHQ-9 for depression, GAD-7 for anxiety) alongside PFS to assess comorbid mental health; tailor treatment accordingly.
Sources
- Piper, B. F., Dibble, S. L., Dodd, M. J., Weiss, M. C., Slater, G., & Paul, S. M. (1989). The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum, 16(6), 751–758. link ↗
- Piper, B. F., Lindsey, A. M., & Dodd, M. J. (1987). Fatigue mechanisms in cancer patients: developing nursing theory. Oncol Nurs Forum, 14(6), 17–23. link ↗
How to cite this page
ScholarGate. (2026, June 3). Piper Fatigue Scale (PFS). ScholarGate. https://scholargate.app/en/oncology-nursing/piper-fatigue-scale
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Brief Fatigue InventoryOncology Nursing↔ compare
- Cancer Fatigue ScaleOncology Nursing↔ compare
- Chalder Fatigue ScaleOncology Nursing↔ compare
- ESASOncology Nursing↔ compare
- MFIOncology Nursing↔ compare